Clinicians Recently Performed the 100,000th Procedure Implanting an ICD Equipped with DX Technology – the World’s Only Single-Lead ICD System Providing Direct Atrial Sensing
They offer hope for people who do not respond to conventional treatments or for whom there is no effective therapy yet available: advanced therapy medicinal products (ATMPs). The first of these novel medications, developed using genetic and cell…
The details of many immune defense mechanisms are still unknown, but a new study sheds light on one such mechanism. Writing in “The EMBO Journal”, researchers led by Oliver Daumke and Misha Kudryashev of the Max Delbrück Center describe exactly how…
Today, the European Commission is proposing more time for companies to apply the In Vitro Diagnostic Medical Devices Regulation (IVDR), under certain conditions. With this revision, the Commission aims to ensure patient care by improving the…
Chemistry on brink of complete transformation
Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening…
Intensive care units (ICUs) commonly have to provide palliative care to patients. But not every medical center has special expertise in palliative medicine. Can telemedicine consultations further improve the palliative care provided in ICU settings?…
The Technology Showcase at CYTO, the annual conference of the International Society for Advancement of Cytometry (ISAC), gives early-stage companies a platform to present their innovation and products to a broad audience:
The Potsdam Science Park is one of the leading life science locations in the Berlin-Brandenburg capital region and beyond. Currently, three major construction projects intend to create generous new office and laboratory spaces. Once finished, they…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply…
